Vision – Improve treatments and find cures for people with ALS

Amyotrophic Lateral Sclerosis Research Program Cover Image
» Click on Image to View Program Booklet

ALSRP Strategic Plan Image
» Click on Image to View Strategic Plan

ALSRP Summary Sheet Image
» Click on Image to View Program Summary Sheet

ALS Research Program Overview Image
» Click on Image to View Program Overview

Amyotrophic Lateral Sclerosis (ALS), also known as "Lou Gehrig's disease," is a degenerative neurological disorder without a cure. For reasons that are not well understood, the nerve cells in the brain and spinal cord that control voluntary muscle movement gradually deteriorate. ALS can be difficult to diagnose because the initial symptoms are both subtle and vague and can be attributed to a number of other conditions. Average life expectancy after diagnosis ranges between 3 to 5 years from the onset of symptoms. It is estimated that 5-10% of all ALS cases are inherited (familial disease) while the remaining 90-95% are sporadic, with unknown etiology and risk factors. There is currently no known cure or therapy to effectively halt the progression of ALS. Evidence from scientific research suggests a mutually inclusive relationship between ALS and military service, with a higher rate of incidence in the Veteran population, without any known reason(s) for this incidence.

The ALSRP is guided by a vision to improve treatments and find cures for people with ALS. Through its award mechanisms and funding recommendations, the ALSRP specifically supports impactful research to develop ALS treatments.

ALSRP Initiatives

Congressional Appropriations

Congressional Appropriations

  • $189.4 million FY07, FY09-22
  • $40 million

Funding Summary


Related Videos

Matt Bellina

ALS Therapy Development Institute
A Consumer’s Perspective: An Increased Sense of Urgency

Dr. Lucie Bruijn

The ALS Association
Targeting Drug Discovery

Last updated Thursday, July 11, 2024